XENE
Xenon Pharmaceuticals Inc
NASDAQ: XENE · HEALTHCARE · BIOTECHNOLOGY
$55.75
+2.24% today
Updated 2026-04-29
Market cap
$5.39B
P/E ratio
—
P/S ratio
718.38x
EPS (TTM)
$-4.36
Dividend yield
—
52W range
$28 – $64
Volume
1.5M
Xenon Pharmaceuticals Inc (XENE) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-13.69M | $45.57M | $-3.32M | $266000.00 | $-18.10M | $-19.57M | $-28.73M | $-34.72M | $-4.63M | $-48.12M | $-69.50M | $-98.43M | $-145.33M | $-181.39M | $-279.12M |
| Capital expenditures | $290000.00 | $526000.00 | $156000.00 | $1.53M | $551000.00 | $279000.00 | $315000.00 | $507000.00 | $1.24M | $2.64M | $2.05M | $2.89M | $5.62M | $3.08M | $799000.00 |
| Depreciation | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | $447000.00 | $414000.00 | $648000.00 | $760000.00 | $3.73M | $2.16M | $2.24M | $2.63M | $2.92M | $5.68M | $10.02M | $20.38M | $32.37M | $50.72M | $53.71M |
| Free cash flow | $-13.98M | $45.05M | $-3.48M | $-1.26M | $-18.65M | $-19.85M | $-29.04M | $-35.23M | $-5.87M | $-50.76M | $-71.55M | $-101.32M | $-150.94M | $-184.46M | $-279.92M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | $34.08M | $-13.38M | $-41.56M | $3.39M | $47.27M | $-43.41M | $20.85M | $131.27M | $-115.96M | — | — | — |